In one paragraphArticle in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Renan César SbruzziLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0003-2206-5502 Adrian GervaisLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0002-1083-5787 Eduarda SgarioniLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0002-3418-0981 Silvia GressLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0009-0002-4314-8630 Helena Suñé LehmenLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0009-0008-8599-1558 Martina Schroeder WissmannMedical Genetics Service, Hospital de Clínicas de Porto Alegre , Porto Alegre, Brazil.ORCID 0000-0001-9121-5688 Bibiana Sampaio de Oliveira FamLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0002-6654-6415 Nathan A CadoreLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0001-6007-7147 Mariléa F FeiraLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0001-7341-8457 Osvaldo ArtigalásMedical Genetics Service, Hospital de Clínicas de Porto Alegre , Porto Alegre, Brazil.ORCID 0000-0002-6325-3086 Giovanna Câmara GiudicelliBioinformatics Core, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0003-4548-5737 Lucy BizienLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0001-9163-9122 Aurélie CobatLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0001-7209-6257 Qian ZhangLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0002-9040-3289 Anne PuelLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0003-2603-0323 Paul BastardLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0002-5926-8437 Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, F-75015, Paris, France.ORCID 0000-0002-7782-4169 Fernanda S L ViannaLaboratory of Genomic Medicine, Center of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID 0000-0001-6339-4869 Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico 3110092025-5Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 518211/2020-00Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 937823/2024-00French National Research Agency ANR-2021-RUS-008Hospital de Clínicas de Porto Alegre 2020-0479
6 · The paper itselfAbstract
Inborn errors of type I IFN (IFN-I) immunity and neutralizing autoantibodies (auto-Abs) against IFN-I (AAN-I-IFNs) impair antiviral immunity and underlie critical COVID-19. Their impact on disease severity in different populations, such as Latin American populations, remains to be better understood. This study assessed the presence of AAN-I-IFNs (anti-IFN-α2, anti-IFN-ω, and anti-IFN-β) in a cohort of 458 COVID-19 patients from southern Brazil, stratified as mild (n = 224) versus non-mild (n = 234), or survivors (n = 369) versus deceased (n = 89). AAN-I-IFNs were detected in 17 patients (3.7%), with increasing prevalence across disease severity, present in one (0.4%) mild case and 16 (6.8%) hospitalized cases (P = 0.006); and eight (2.2%) survivors and nine (10.1%) deceased cases (P = 0.008). Anti-IFN-α2 and anti-IFN-ω auto-Abs were most frequently detected, while anti-IFN-β auto-Abs were found in one patient. Our findings highlight the role of AAN-I-IFNs underlying COVID-19 severity in a southern Brazilian population.
Identifiers
PMID42836780
PMCPMC13641011
What OpenQuestion holds
Textmetadata
Read underepoch 390